|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nagini S: Carcinoma of the stomach: A
review of epidemiology, pathogenesis, molecular genetics and
chemoprevention. World J Gastrointest Oncol. 4:156–169. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: A representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Micic D, Cvijovic G, Trajkovic V, Duntas
LH and Polovina S: Metformin: Its emerging role in oncology.
Hormones (Athens). 10:5–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim YI, Kim SY, Cho SJ, Park JH, Choi IJ,
Lee YJ, Lee EK, Kook MC, Kim CG, Ryu KW and Kim YW: Long-term
metformin use reduces gastric cancer risk in type 2 diabetics
without insulin treatment: A nationwide cohort study. Aliment
Pharmacol Ther. 39:854–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vallianou NG, Evangelopoulos A and Kazazis
C: Metformin and cancer. Rev Diabet Stud. 10:228–235. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Varjosalo M and Taipale J: Hedgehog
signaling. J Cell Sci. 120:3–6. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ingham PW: Hedgehog signaling. Cold Spring
Harb Perspect Biol. 4(pii): a0112212012.PubMed/NCBI
|
|
11
|
di Magliano M Pasca and Hebrok M: Hedgehog
signalling in cancer formation and maintenance. Nat Rev Cancer.
3:903–911. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suzuki H, Minegishi Y, Nomoto Y, Ota T,
Masaoka T, van den Brink GR and Hibi T: Down-regulation of a
morphogen (sonic hedgehog) gradient in the gastric epithelium of
helicobacter pylori-infected mongolian gerbils. J Pathol.
206:186–197. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Berman DM, Karhadkar SS, Maitra A, De Oca
R Montes, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman
JR, et al: Widespread requirement for Hedgehog ligand stimulation
in growth of digestive tract tumours. Nature. 425:846–851. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma X, Chen K, Huang S, Zhang X, Adegboyega
PA, Evers BM, Zhang H and Xie J: Frequent activation of the
hedgehog pathway in advanced gastric adenocarcinomas.
Carcinogenesis. 26:1698–1705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alexander GC, Sehgal NL, Moloney RM and
Stafford RS: National trends in treatment of type 2 diabetes
mellitus, 1994–2007. Arch Intern Med. 168:2088–2094. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Corte CM Della, Ciaramella V, Di Mauro C,
Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E,
Troiani T, De Vita F, et al: Metformin increases antitumor activity
of MEK inhibitors through GLI1 downregulation in LKB1 positive
human NSCLC cancer cells. Oncotarget. 7:4265–4278. 2016.PubMed/NCBI
|
|
18
|
Zheng L, Yang W, Wu F, Wang C, Yu L, Tang
L, Qiu B, Li Y, Guo L, Wu M, et al: Prognostic significance of AMPK
activation and therapeutic effects of metformin in hepatocellular
carcinoma. Clin Cancer Res. 19:5372–5380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sinnett-Smith J, Kisfalvi K, Kui R and
Rozengurt E: Metformin inhibition of mTORC1 activation, DNA
synthesis and proliferation in pancreatic cancer cells: Dependence
on glucose concentration and role of AMPK. Biochem Biophys Res
Commun. 430:352–357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rozengurt E, Sinnett-Smith J and Kisfalvi
K: Crosstalk between insulin/insulin-like growth factor-1 receptors
and G protein-coupled receptor signaling systems: A novel target
for the antidiabetic drug metformin in pancreatic cancer. Clin
Cancer Res. 16:2505–2511. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ersoy C, Kiyici S, Budak F, Oral B, Guclu
M, Duran C, Selimoglu H, Erturk E, Tuncel E and Imamoglu S: The
effect of metformin treatment on VEGF and PAI-1 levels in obese
type 2 diabetic patients. Diabetes Res Clin Pract. 81:56–60. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakamura M, Ogo A, Yamura M, Yamaguchi Y
and Nakashima H: Metformin suppresses sonic hedgehog expression in
pancreatic cancer cells. Anticancer Res. 34:1765–1769.
2014.PubMed/NCBI
|
|
23
|
Ingham PW and McMahon AP: Hedgehog
signaling in animal development: Paradigms and principles. Genes
Dev. 15:3059–3087. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee J, Platt KA, Censullo P and i Altaba A
Ruiz: Gli1 is a target of Sonic hedgehog that induces ventral
neural tube development. Development. 124:2537–2552.
1997.PubMed/NCBI
|
